alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 3,276–3,300 of 27,380 studies, newest first · page 132 of 1096.

September 2025 25

  1. 2025-09-01

    APOE genotype-dependent differences in human astrocytic energy metabolism

    ✓ Peer-reviewed Genetics Frontiers in cellular neuroscience

    Key finding: ATP Seahorse assay revealed a reduced mitochondrial and glycolytic ATP production in APOE4 iAstrocytes. +4 more findings

    Full summary, score breakdown and related studies → Original source

  2. 2025-09 month only

    Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: The study included 381 MCSA and 584 BioFINDER-2 participants. +4 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2025-09 month only

    Combining Lumipulse p-tau217 and Aβ42/40 as confirmatory tests for Aβ positivity prior to disease-modifying therapy

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Testing an Alzheimer's disease continuum cohort, the area under the curve (AUC), sensitivity, specificity, and accuracy for the p-tau217/Aβ42 ratio reached 0.961, 93%, 92%, and 93%, respectively. +4 more findings

    Full summary, score breakdown and related studies → Original source

  4. 2025-09 month only

    Traumatic brain injury, changes in plasma amyloid, tau, and neurodegenerative biomarkers, and dementia risk

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: After the median time of incident TBI, Aβ42/Aβ40 levels remained lower for 9.3 years, and pTau181, NfL, and GFAP remained elevated for 8.5, >13.8, and 12.7 years, respectively. +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2025-09 month only

    The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Phosphorylated tau (p-tau) species (153, 181, 217, 231) increased early in preclinical AD but were reduced with gantenerumab-mediated Aβ plaque reduction. +4 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2025-09 month only

    Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: 55-80 years of age were screened (N = 63,124). +4 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2025-09-01

    Efficacy and APOE ε4-stratified risk of donanemab in Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials

    ✓ Peer-reviewed Treatments Journal of Alzheimer's disease : JAD

    Key finding: Donanemab modestly reduced cognitive decline compared to placebo: ADAS-Cog13 (MD, -1.86), CDR-SB (MD, -0.36), MMSE (MD, 0.64), and iADRS (MD, 3.19), with similar effects across tau subgroups. +1 more finding

    Full summary, score breakdown and related studies → Original source

  8. 2025-09-01

    Stroke–heart syndrome and risk of incident dementia among patients with first‐ever ischemic stroke: A territory‐wide population‐based cohort study

    ✓ Peer-reviewed Vascular contributions Alzheimer s & Dementia

    Key finding: Of the 130,605 included patients with ischemic stroke, 12,696 (9.7%) patients developed SHS. +4 more findings

    Full summary, score breakdown and related studies → Original source

  9. 2025-09-01

    Unifying Vascular Injury and Neurodegeneration: A Mechanistic Continuum in Cerebral Small Vessel Disease and Dementia

    ✓ Peer-reviewed Vascular contributions European Journal of Neuroscience

    Key finding: Emerging evidence indicates that CSVD is not merely a coexisting vascular condition but an active amplifier of neurodegeneration, operating through a self-perpetuating cascade of microvascular injury, blood-brain barrier (BBB) breakdown, and glymphatic system dysfunction.

    Full summary, score breakdown and related studies → Original source

  10. 2025-09-01

    Supporting decision making for individuals living with dementia and their care partners with knowledge translation: An umbrella review

    ✓ Peer-reviewed End-of-life care Alzheimer s & Dementia

    Key finding: Overall, our umbrella review offers insights into the beneficial impacts of KT interventions, such as increased knowledge and confidence, and decreased decisional conflicts.

    Full summary, score breakdown and related studies → Original source

  11. 2025-09-01

    Occurrence of advance care planning for persons with dementia, cancer and other chronic-progressive diseases in general practice: longitudinal analysis of data from health records linked with administrative data

    ✓ Peer-reviewed End-of-life care BMJ Open

    Key finding: In adjusted analyses, the rate of first ACP conversation for persons with organ failure was the lowest (IRR 0.70 (95% CI 0.68 to 0.73)). +4 more findings

    Full summary, score breakdown and related studies → Original source

  12. 2025-09-01

    Nature and Management of Delirium in the Intensive Care Unit

    ✓ Peer-reviewed Clinical safety Psychiatric Annals

    Key finding: Its occurrence is associated with increased morbidity, increased cost of care and prolonged hospital stays, an increased rate of cognitive disorders, including early onset dementia, and higher mortality rates.

    Full summary, score breakdown and related studies → Original source

  13. 2025-09-01

    Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy

    ✓ Peer-reviewed Disease mechanisms Current Drug Metabolism

    Key finding: Impaired glucose metabolism, mitochondrial dysfunction, oxidative stress, and lipid dysregulation are frequently observed in AD brains, suggesting that metabolic dysfunction may exacerbate neurodegeneration and cognitive deficits.

    Full summary, score breakdown and related studies → Original source

  14. 2025-09-01

    Emerging Role of Oligodendrocytes Malfunction in the Progression of Alzheimer's Disease

    ✓ Peer-reviewed Disease mechanisms Journal of Neuroimmune Pharmacology

    Key finding: While much attention has focused on neurons and microglia, recent studies underscore the significant yet understudied roles of oligodendrocytes (OL) and oligodendrocyte precursor cells (OPC) in AD pathology.

    Full summary, score breakdown and related studies → Original source

  15. 2025-09-01

    A Case of Late‐Onset Semantic Dementia With Right‐Predominant Temporal Lobe Atrophy due to Primary Tauopathy

    ✓ Peer-reviewed Disease mechanisms Psychogeriatrics

    Key finding: Brain MRI revealed right-predominant atrophy in the amygdala, hippocampus, and anterior temporal lobes. +2 more findings

    Full summary, score breakdown and related studies → Original source

  16. 2025-09-01

    A phenotypic screen for novel small molecules that correct tau‐mediated pathologies in human frontotemporal dementia neurons

    ✓ Peer-reviewed Disease mechanisms Alzheimer s & Dementia

    Key finding: Screening a 19,786-compound chemical diversity library, we identified > 100 compounds that corrected nuclear membrane defects in MAPT IVS10+16 neurons, with 23 demonstrating robust dose-dependent rescue. +4 more findings

    Full summary, score breakdown and related studies → Original source

  17. 2025-09-01

    Emerging roles for innate and adaptive immunity in tauopathies

    ✓ Peer-reviewed Disease mechanisms Cell Reports

    Key finding: Tau aggregation and neuronal loss associated with this pathology are accompanied by robust neuroinflammation. +2 more findings

    Full summary, score breakdown and related studies → Original source

  18. 2025-09-01

    C9orf72 Repeat Expansion Induces Metabolic Dysfunction in Human iPSC ‐Derived Microglia and Modulates Glial‐Neuronal Crosstalk

    ✓ Peer-reviewed Inflammation and the immune system Glia

    Key finding: Our results showed that microglia are particularly susceptible to metabolic disturbances. +2 more findings

    Full summary, score breakdown and related studies → Original source

  19. 2025-09-01

    Targeting the miR‐96‐5p/Cathepsin B Pathway to Alleviate Neuron‐Derived Neuroinflammation in Alzheimer's Disease

    ✓ Peer-reviewed Inflammation and the immune system MedComm

    Key finding: In the present study, we found that CTSB expression was abnormally elevated in the hippocampus of 3×Tg mice and was regulated by miR-96-5p. +3 more findings

    Full summary, score breakdown and related studies → Original source

  20. 2025-09-01

    Facets of language performance in early‐onset and late‐onset Alzheimer's disease dementia

    ✓ Peer-reviewed Brain tissue and pathology Alzheimer s & Dementia

    Key finding: Based on data from their first NACC visit with AD, there was considerable heterogeneity in language performance across people with EOAD and LOAD. +4 more findings

    Full summary, score breakdown and related studies → Original source

  21. 2025-09-01

    The National Dementia Workforce Study: Overview

    ✓ Peer-reviewed Long-term cohort studies Journal of the American Geriatrics Society

    Key finding: Their care needs incur nearly $30,000 more in mean annual costs per person compared to peers without dementia, and overall costs are expected to rise to $1.6 trillion within 15 years.

    Full summary, score breakdown and related studies → Original source

  22. 2025-09-01

    Objective physical activity in people with young onset dementia, late onset dementia, and without dementia: A UK Biobank study

    ✓ Peer-reviewed Long-term cohort studies Journal of Alzheimer s Disease

    Key finding: There were no significant differences between people with young onset dementia and the young onset control group.

    Full summary, score breakdown and related studies → Original source

  23. 2025-09-01

    Objective physical activity and Alzheimer's disease burden in the population‐based Rotterdam Study

    ✓ Peer-reviewed Long-term cohort studies Alzheimer s & Dementia

    Key finding: Physical activity was not associated with plasma Aβ42/Aβ40, p-tau217, or brain Aβ burden 7 years later. +4 more findings

    Full summary, score breakdown and related studies → Original source

  24. 2025-09-01

    Clinical progression on CDR‐SB©: Progression‐free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations

    ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s & Dementia

    Key finding: PFT is longer at CDR-SB ≤ 2.0 (1-2 years) and shorter at CDR-SB ≥ 5 (≤ 0.33) in the Alzheimer's Disease Neuroimaging Initiative cohort. +4 more findings

    Full summary, score breakdown and related studies → Original source

  25. 2025-09-01

    Rates of clinical progression according to biological Alzheimer's disease stages

    ✓ Peer-reviewed Mild cognitive impairment Alzheimer s & Dementia

    Key finding: Our results highlight the prognostic value of biological AD staging. +4 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →